Digital NAFLD Summit 2021


16-17 September 2021
N. Poster
Poster title
Applicant name
  PO-010 Portohepatic hemodinamic disorders and increased blood ammonia at the steatohepatitis patients with initial liver fibrosis. Tatiana Ermolova Received Received
  PO-012 Metabolic, biochemical, histopathological, and transcriptomic effects of resmetirom (MGL-3196) in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH Michael Feigh Received Received
  PO-027 The NIF mouse - a unique way to distinguish between immunological and metabolic effects of NASH drug candidates Sofia Mayans Received Received
  PO-030 Anti-oxidant, anti-inflammatory, and anti-fibrotic properties of triterpenic acids and phenylpropanoids on in vitro models of non-alcoholic steatohepatitis Noel Salvoza Received Received
  PO-035 Is it a HIIT? High-Intensity Interval Training (HIIT) for the management of Non-alcoholic Steatohepatitis: patient experiences and perspectives Shelley Keatng Received Received
  PO-038 The sustainable development goals as a driver of multisectoral action on NAFLD: the NAFLD-SDG framework Jeffrey V Lazarus Received Received
  PO-043 Effects of bariatric surgery on quality of life in patients with non-alcoholic fatty liver disease Jesús Funuyet-Salas Received Received
  PO-047 Impact of coping, vitality and metabolic pathology on depressive symptoms of patients with non-alcoholic fatty liver disease Jesús Funuyet-Salas Received Received
  PO-048 Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy Maria Pilar Ballester Ferré Received Received
  PO-052 Metabolic, biochemical, histopathological, and transcriptomic effects of dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH Michael Feigh Received Received
  PO-060 Evaluating use of small molecule inhibitors of integrin function in NAFLD Emma Shepherd Received Received
  PO-070 Design and evaluation of autophagy-inducing particles: towards a treatment of fatty liver disease? Stavroula Zagkou Received Received
  PO-073 Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with nonalcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D) Stephen Harrison Received Received
  PO-075 Crosstalk between ileal macrophage polarization and bacterial translocation in NASH: Role of PPAR alpha/delta dual activation Andrew Hakeem Received Received
  PO-078 A Novel Quantitative Ultrasound Technique for Identifying Nonalcoholic Steatohepatitis Feng Gao Received Received
  PO-079 Receptor Activity-Modifying Protein (RAMP2) alters glucagon trafficking in hepatocytes with functional effects on signalling EmmaRose McGlone Received Received
  PO-080 Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven NAFLD: a pilot study Zhongwei Chen Received Received
  PO-082 Sex influence the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven NAFLD Gang Li Received Received
  PO-083 Biomaging, biochemical and genetic markers to stratify patients with metabolic associated fatty liver disease (MAFLD) in clinical practice: a single center cohort study Laura De rosa Received Received
  PO-087 Rescuing the brain from non-alcoholic fatty liver disease: role of the monocarboxylate transporter-1 Anna Hadjihambi Received Received
  PO-088 Silencing Cyclin M4 induces hepatic magnesium accumulation to resolve NASH Jorge Simón Received Received
  PO-091 Diagnostic accuracy of liver steatosis measurements using artificial intelligence Michael House Received Received
  PO-092 Metabolic association and liver fibrosis relationship in patients with non-alcoholic fatty liver disease and gallstone disease. Tatyana Krolevets Received Received
  PO-095 GTX-011 improves portal hypertension, liver fibrosis and endothelial dysfunction in pre-clinical non-alcoholic steatohepatitis Jordi Gracia-Sancho Received Received
  PO-100 Tocotrienol Rich Fraction Activates Farnesoid-X Receptor And Modulates Metabolites Profile of Non-Alcoholic Fatty Liver Disease In Mice Model MohdDanial Mohd Efendy Goon Received Received
  PO-101 Characterization of disease progression and pharmacological intervention in the GAN diet-induced obese mouse model of NASH with advanced fibrosis and hepatocellular carcinoma Michael Feigh Received Received
  PO-102 Subclinical liver damage detection by NMR spectroscopy María Martín Grau Received Received
  PO-107 Hepatic steatosis contributes to the development of muscle atrophy via inter-organ crosstalk Kenneth Pasmans Received Received
  PO-110 Hepatocyte cholesterol content modulates glucagon receptor signalling EmmaRose McGlone Received Received
  PO-111 Transcriptomic signature of high fat diet murine models of NAFLD and its modulation by anti-steatotic treatments: a meta-analysis Isabel Fuster-Martínez Received Received
  PO-115 Lower serum zinc levels are associated with severe hepatic necro-inflammation in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) Sui-Dan Chen Received Received
  PO-117 Myeloid-specific fatty acid transport protein 4 deficiency in mice induces a shift towards M2 macrophages that leads to aggravation of NASH after high-fat/high-cholesterol feeding Deniz Gcebe Received Received
  PO-124 Microbiome metabolites aggravate hepatic lipid deposition by decreasing mitochondrial function in an in vitro model of non-alcoholic fatty liver disease Paula Boeira Received Received
  PO-131 Sterol lipids are associated with the plasticity of adipose tissue and promote a different response in women and men with severe obesity. Gerard Baiges Received Received
  PO-132 A fast-induced model of fibrosing NASH: outcomes in different mice strains Gabriel Bacil Received Received
  PO-139 The incremental Intrahepatic and extrahepatic cholangiocarcinoma risks in NAFL, NASH, and MAFLD patients: systematic review and meta-analysis Boby Pratama Putra Received Received
  PO-140 New INSIGHTS into the role of MITOCHONDRIA in the development of NON-ALCOHOLIC FATTY LIVER DISEASE Ins C.M. Simes Received Received
  PO-144 NAFLD vs MAFLD: South Asian NAFLD patients dont favour name change Prajna Anirvan Received Received
  PO-149 One in ten cases of severe liver disease in the general population is attributable to type 2 diabetes Ville Tapio Mnnist Received Received
  PO-151 Use of non-invasive tests to assess NAFLD patients in routine clinical practice Emmanuel A Tsochatzis Received Received
  PO-153 Phosphatidylcholine attenuates the onset of a diet induced-NAFLD in mice Victor Sánchez Received Received
  PO-157 AGILE3 development and validation: novel FibroScan based score to diagnose advanced fibrosis in non alcoholic fatty liver disease patients Jerome Boursier Received Received
  PO-160 Prognostic value of AGILE scores in patients with non alcoholic fatty liver disease Jerome Boursier Received Received
  PO-162 Cross-validation of non-invasive diagnostics for NAFLD in individuals with type 1 diabetes jonathan mertens Received Received
  PO-164 Selective modulation of metabotropic glutamate receptor 5 protects obese-high fat diet mice from oxidative stress and lipid accumulation Clarissa Berardo Received Received
  PO-165 Increased gut permeability may be associated with bacterial protease activity, not intestinal inflammation in patients with significant liver disease due to NAFLD Roberta Forlano Received Received
  PO-166 The BAST score performs predicts the presence of liver disease better than FIB-4 and NAFLD fibrosis score in a cohort of patients with type-2 diabetes mellitus in primary care Roberta Forlano Received Received
  PO-167 Liver senescence is linked to the development of NAFLD in young mice independently of obesity IoannisI. Moustakas Received Received
  PO-168 Fibroblast Growth Factor 21 (FGF21) is a hepatokine involved in NAFLD progression. Rocío Gallego-Durán Received Received
  PO-169 Quantification of EPCAM CD133 microvesicles: a MAFLD biomarker Sheila Gato Zambrano Received Received
  PO-170 MiRNA-200b-3p overexpression is linked to NASH phenotype in both human and animal settings Rocío Montero-Vallejo Received Received
  PO-171 Statin use is associated with significantly lower risk of high-risk NAFLD among patients with type 2 diabetes. A propensity-matched analysis from NHANES 2017-2018 Eduardo Vilar Gomez Received Received
  PO-172 Relationship between serum and hepatic levels of Zn and Fe versus fatty acid composition in a rat model of NASH LauraGiuseppina Di Pasqua Received Received
  PO-174 Waist and Hip Circumference are Independently Associated with Risk of Liver Disease in Population-Based Studies Oscar Danielsson Received Received
  PO-175 The relationship between the frequency of drinking and incidence of fatty liver in Japanese cohort undergoing health checkups during the period 2008-2019 Aya Sugiyama Received Received
  PO-176 The natural history of pediatric Non-alcoholic Fatty Liver Disease: a long term follow-up study. Laura Draijer Received Received
  PO-178 Neddylation inhibition reduces liver steatosis in MAFLD mice models by promoting hepatic fatty acid oxidation via DEPTOR-mTOR axis MARINA SERRANO MACIÁ Received Received
  PO-182 Association of PNPLA3 with the development of arterial stiffness in young patients with non-alcoholic fatty liver disease Anastasiia Radchenko Received Received
  PO-184 Vitamin D Regulated MicroRNA Pathway and the Molecular Pathogenesis of Metabolic-associated Fatty Liver Disease Zixuan Zhang Received Received
  PO-186 Short-term gluten-free diet is effective in reducing Controlled Attenuation Parameter and Body Mass Index in patients with Non-Alcoholic Steatohepatitis Angelo Armandi Received Received
  PO-187 INT-747 ameliorates NASH pathogenesis by inhibiting hepatic diacylglycerol acyltransferase -2 mediated triglyceride synthesis in mice Balasubramaniyan Vairappan Received Received
  PO-190 Single-cell analysis of NAFLD induced by high fat diet in rat Fumihiko Takeuchi Received Received
  PO-193 Anti-inflammatory and anti-fibrotic effect of icosabutate as mono- or combination therapy with a GLP-1 receptor agonist, a FXR agonist or an ACC inhibitor in a dietary mouse model of progressive fibrosis David Fraser Received Received
  PO-197 Menopausal women with NAFLD show impaired metabolism of branched chain amino-acids Roberta Forlano Received Received
  PO-203 4-methylpyrazole attenuates the development of diet-induced NAFLD Katharina Burger Received Received
  PO-205 Mitochondria-targeted antioxidant based on caffeic acid AntiOxCIN4 prevented hepatic lipid accumulation by avoided Western Diet-induced autophagic blockage Ricardo Fernando Santos Amorim Received Received
  PO-206 The activation of Liver X Receptor alpha in the gut protects the liver by the NASH-related damage gessica lioci Received Received
  PO-207 Nonalcoholic steatohepatitis modifies liver and plasma phospholipids profile from patients with morbid obesity Helena Castañé Received Received
  PO-208 A little is better than nothing: very low alcohol consumption is associated with lower prevalence of cirrhosis and HCC in patients with NAFLD Bernardo Stefanini Received Received
  PO-215 A 3D in vitro throughput-based discovery approach for ing NASH drug candidates Simon Strbel Received Received
  PO-220 Rising indication of non-alcoholic steatohepatitis as transplant indication in historically low risk areas Laura Martínez Arenas Received Received
  PO-221 TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models Miriam Longo Received Received
  PO-222 The I148M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in nonalcoholic fatty liver disease patients gains value Erika Paolini Received Received
  PO-223 MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients Marica Meroni Received Received
  PO-225 Outcomes of postmenopausal women with non-alcoholic fatty liver disease (NAFLD) Chioma Izzi-Engbeaya Received Received
  PO-229 Preclinical animal models for nonalcoholic steatohepatitis (NASH) and their pharmacological validation Gabe Berkowitz Received Received
  PO-230 Targeting the pro-inflammatory phenotype of adipose tissue macrophages using a dextran-nanocarrier ameliorates liver fibrosis and inflammation in a mouse model of NAFLD Celia Martínez Sánchez Received Received
  PO-231 Cognitive dysfunction is associated with systemic inflammation and neuroinflammation in a rodent model of non-alcoholic steatohepatitis Anne Catrine Daugaard Mikkelsen Received Received
  PO-234 Assessment of systemic inflammation by 3D MR Elastography in obese patients treated with bariatric surgery Jiahui Li Received Received
  PO-237 Gender differences in characteristics of adolescents with non-obese nonalcoholic fatty liver disease Oyekoya Ayonrinde Received Received
  PO-239 Ankle brachial index and all-cause and cardiovascular mortality in patients with NAFLD Stefano Ciardullo Received Received
  PO-240 Intestinal microbiota in obese children with non-alcoholic fatty liver disease depending on the gallbladder function Nataliya Zavhorodnia Received Received
  PO-242 Reduction in fibrosis and steatohepatitis imaging and biomarkers in 52-week resmetirom non-alcoholic steatohepatitis trial Stephen Harrison Received Received
  PO-244 Intestinal microbiota features in obese children with non-alcoholic fatty liver disease depending on the grade of steatosis Nataliya Zavhorodnia Received Received
  PO-249 Identification of new potential biomarkers to follow steatohepatitis in patients with Non-Alcoholic/Metabolic Associated Fatty Liver disease Douglas Maya Miles Received Received
  PO-250 Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice Mohammad Kabbani Received Received
  PO-251 increase metabolic dysfunction fatty liver disease related hepatocellular carcinoma in Egypt over a decade of period Yasser Fouad Received Received
  PO-253 A cholestatic pattern predicts liver-related events in patients with nonalcoholic fatty liver disease Grazia Pennisi Received Received
  PO-258 Hepatologists awareness and knoweledge towards NAFLD and familiarity with renaming from NAFLD to MAFLD Yasser Fouad Received Received
  PO-259 Eating habits in patients affected by non-alcoholic steatohepatitis and type 2 diabetes mellitus Lucia Brodosi Received Received
  PO-260 EUropean Patient cEntric clinicAl tRial pLatform (EU-PEARL): generating an integrated research platform to revolutionizing drug development in NASH Juan M. Pericàs Received Received
  PO-261 Liver related and extrahepatic events occurrence in patients with non alcoholic fatty liver disease: a competing risk analysis Grazia Pennisi Received Received
  PO-269 Hepatoprotective activity of Juglans regia stem bark ethanolic extract on CCl4 induced liver injury rat model Bipindra Pandey Received Received
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 16/09/2021 TO 16/09/2022
Featured Poster
Vote poster
Poster Discussion

Logo Draft
Logo Cert